We are excited to announce that our Principal, Ms. Pauli Wong, has been appointed as the Honorary IP Advisor by the Hong Kong Medical & Healthcare Device Industries Association (HKMHDIA) for the term 2025-2026. She will provide advice and guidance to support HKMHDIA’s mission in advocating for streamlined regulatory policies to position Hong Kong as a leader in medical technologies. 

Pauli has served many HKMHDIA members in the life sciences and medical devices sectors as their patent attorney over the past few years. She is eager to provide strategic guidance for the association, leveraging her deep understanding of intellectual property to help HKMHDIA members safeguard their innovations and enhance their competitive edge. 

We are confident that Pauli's expertise and dedication will greatly benefit HKMHDIA and its members, driving innovation and success in the life sciences and medical devices sector of Hong Kong. 

Our Past Events

Recommended Insights

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

28 October 2020
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]

China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH

20 July 2020
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]

How to Protect a Crystal Form (Polymorph) Patent in China

4 June 2025
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

Everything you need to know about Patent Term Adjustment (PTA) in China

7 May 2024
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
Top crossarrow-right